Imagion Biosystems Ltd. · ASX:IBX
Imagion Biosystems — Investor Presentation (February 2023)
27 slides from Imagion Biosystems's investor presentation, Feb 6, 2023
Slide 1: Changing the way we look at cancer
Changing the way we look at cancer For personal use only Investor Presentation 6 February 2023 Imagion Biosystems Limited ImagionBiosystems.com ASX:IBX
Slide 2: Disclaimers
Disclaimers Imagionbiosystems.com For personal use only This investor presentation (Presentation) has been prepared by Imagion Biosystems Limited (Imagion or the Company). This presentation does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to s
Slide 3: Imagion Biosystems Overview
Imagion Biosystems Overview Imagionbiosystems.com For personal use only We are a clinical stage medical imaging company Imagion Biosystems developing next generation molecular imaging ASX:IBX technologies Market cap: ~$25 million Cash at 31 Dec 2022: $4.4 million Innovative medical imaging using bio
Slide 4: Investment Highlights
Investment Highlights Imagionbiosystems.com For personal use only $ Product Pipeline Addresses MagSense® Technology 4 Key Initial Clinical Large Markets & Unmet Will Transform Cancer Multiple Revenue Strong Leadership Milestones Achieved Needs Diagnosis Opportunities and Advisory Boards First produc
Slide 5: A Global Medical Need
For personal use only 01 A Global Medical Need $100 billion spent annually to diagnose or detect Each year cancer kills 9 million people globally cancer, yet cancer continues to be a leading cause of mortality and morbidity. 5
Slide 6: A Growing Global Health Problem
A Growing Global Health Problem Imagionbiosystems.com For personal use only 1 in 3 people are affected by cancer US$100 BILLION CANCER DIAGNOSTICS MARKET $30,000 $26.0b $25,000 $20.1b $20,000 Millions (USD) $15.5b $15,000 $9.6b $10,000 $8.9b $7.2b $5.9b $3.1b $4.6b $5,000 $- Blood Pancreatic Kidney
Slide 7: Clear Unmet Medical Need
Clear Unmet Medical Need Imagionbiosystems.com For personal use only Anatomical images can’t differentiate benign from malignant lesions 7
Slide 8: MagSense Technology
For personal use only 02 MagSense® Technology 8
Slide 9: Enabling Molecular Imaging
Enabling Molecular Imaging Imagionbiosystems.com For personal use only MagSense® Technology aims to transform how medical imaging can detect and diagnose cancer Non-invasive – a safe and non-surgical solution to detect cancer Conventional methods are not specific and can only identify a region of in
Slide 10: How It Works
How It Works Imagionbiosystems.com For personal use only Bio-safe magnetic nanoparticles are attracted to the tumor and detected Patients are given a low dose injection of the nanoparticle imaging agent Targeting molecules affixed to the nanoparticles, ensure high specificity for the cancer, and cau
Slide 11: MagSense Molecular Imaging
MagSense® Molecular Imaging Imagionbiosystems.com For personal use only 1 2 3 4 Clinical assessment MagSense® nanoparticle MRI detects change in Physician sees molecular identifies need for test imaging agent given to image contrast from image signature if tumor patient imaging agent present Works w
Slide 12: How It Works - Video
How It Works - Video Imagionbiosystems.com For personal use only Click play to watch video in browser 12
Slide 13: Broad Commercial Applicability
Broad Commercial Applicability Imagionbiosystems.com For personal use only MagSense® imaging agents can be 1 Brain Cancer developed for many types of solid tumors 2 Lung Cancer and can be used at multiple stages of 3 Breast Cancer diagnosis including primary diagnosis, staging, and monitoring the ef
Slide 14: The Phase I Clinical Study
The Phase I Clinical Study Imagionbiosystems.com For personal use only Detection of Nodal Metastases in HER2+ Breast Cancer No issues of safety or tolerability related to the imaging agent reported to date Data reported show the imaging agent results in a detectable magnetic signature by both imagin
Slide 15: MagSense Imaging with MRI
MagSense Imaging with MRI ® Imagionbiosystems.com For personal use only Changing the way we look at cancer Pre-Dose T2 Data from the Phase I study indicates our molecularly targeted nanoparticles could be effective in detecting nodal disease when used in conjunction with conventional MRI scanners Im
Slide 16: Growth Strategy
For personal use only 03 Growth Strategy 16
Slide 17: Leveraging MRI
Leveraging MRI Imagionbiosystems.com For personal use only Accelerating our path to commercial product The Market Path to Commercialisation R&D Benefits Increases addressable market by Path to market simpler, Pipeline of targeted imaging now targeting the large installed eliminating the challenges a
Slide 18: Business Strategy
Business Strategy For personal use only Use MagSense® HER2 Expand the pipeline Collaborate in other Create a high-value Test as a commercial biomedical applications biomedical portfolio launchpad Build a pipeline of diagnostic imaging agents Generate revenue through Align with strategic partners Cur
Slide 19: MagSense Product Pipeline
MagSense® Product Pipeline Imagionbiosystems.com For personal use only Applying targeted imaging to other cancers Note: The pipeline above provides no guidance as to timing and is indicative and subject to change 19
Slide 20: Compelling Business Model
Compelling Business Model Imagionbiosystems.com For personal use only Proprietary Consumables Drive Growth & Profitability Injectable Each Cancer Test Billable MagSense® ~$1,500 USD* Imaging Agents ~80% Gross Margin* Direct Sales Partnerships Licensing Tests can be sold to Enables strategic Licensin
Slide 21: Leadership and Financials
For personal use only 04 Leadership and Financials 21
Slide 22: Experienced Board and Management
Experienced Board and Management Imagionbiosystems.com For personal use only Commercially focused team with deep industry & clinical experience ROBERT PROULX YALIA JAYALAKSHMI MICHAEL HARSH DAVID LUDVIGSON DIANNE ANGUS CHAIRMAN & CEO CHIEF DEVELOPMENT OFFICER NON-EXEC DIRECTOR NON-EXEC DIRECTOR NON-
Slide 23: Scientific Advisory Board
Scientific Advisory Board Imagionbiosystems.com For personal use only Collective expertise in oncology, medical imaging, nanotechnology, clinical trial design DR JOHN HAZLE PROF LISA HORVARTH DR ROBERT IVKOV SCIENTIFIC ADVISORY BOARD CHAIR • Director, Department of Medical Oncology, • Expertise in r
Slide 24: Collaborators and Partners
Collaborators and Partners Imagionbiosystems.com For personal use only MD Anderson Cancer Center - In 2015 the MD Anderson established a Magnetic Relaxometry Research Laboratory to help validate the Imagion technology for various cancer targets World class scientific collaborations & partnerships: U
Slide 25: Capital and Financial Snapshot
Capital and Financial Snapshot Imagionbiosystems.com For personal use only Ordinary shares on issue 1,121 million Imagion ended Q4 2022 with $4.4 million Listed and unlisted options 290 million Share price (3 February 2023) $0.022 R&D tax incentive of $2.5 million 12-month range $0.02 - $0.071 recei
Slide 26: Historical Cash Flows
Historical Cash Flows Imagionbiosystems.com For personal use only 2020 2021 2022 Q1 AUD Q2 AUD Q3 AUD Q4 AUD Q1 AUD Q2 AUD Q3 AUD Q4 AUD Q1 AUD Q2 AUD Q3 AUD Q4 AUD Operating '000 '000 '000 '000 '000 '000 '000 '000 ’000 ’000 ‘000 ‘000 Receipts from customers 50 26 82 65 41 48 34 84 95 143 88 88 Paym
Slide 27: For personal use only
For personal use only www.imagionbiosystems.com info@imagionbio.com ASX:IBX
Imagion Biosystems — Investor Presentation (February 2023) on 6ix